Payment overview · 2025
General Payments
$955.24
55 reported records · 11 companies
Healthcare provider profile · identity verified
Rodolfo A Munera, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · CLIFTON, NJ · NPI 1154382760
Verified facts
What the public records show
CMS Open Payments records show Rodolfo A Munera, MD received $955.24 in general payments during 2025 across 55 reported records.
Gilead Sciences, Inc. accounted for 45.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Biktarvy, Dovato, Farxiga, Jardiance, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Biktarvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $430.00 | 45.0% | 22 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $146.91 | 15.4% | 11 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $114.54 | 12.0% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $68.15 | 7.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.00 | 5.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.95 | 4.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.07 | 3.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.54 | 2.1% | 1 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $18.89 | 2.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.69 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.50 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $937.86 | 54 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $125.77 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $97.16 | 6 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $71.19 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $68.15 | 4 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $39.12 | 3 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 32 | exact normalized | Medicare Part D |
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 88 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 173 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 155 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 30 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
32 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
45 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
155 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
51 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 696 | 239 |
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 187 |
| Metformin Hcl | Metformin Hcl | 416 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 413 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 130 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 352 | 156 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 109 |
| Losartan Potassium | Losartan Potassium | 330 | 91 |
| Fluticasone Propionate | Fluticasone Propionate | 278 | 130 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 254 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 112 |
| Simvastatin | Simvastatin | 202 | 65 |
| Famotidine | Famotidine | 200 | 88 |
| Alprazolam | Alprazolam | 192 | 64 |
| Omeprazole | Omeprazole | 182 | 66 |
| Jardiance | Empagliflozin | 173 | 35 |
| Ammonium Lactate | Ammonium Lactate | 172 | 54 |
| Baclofen | Baclofen | 168 | 94 |
| Meclizine Hcl | Meclizine Hcl | 168 | 70 |
| Gabapentin | Gabapentin | 166 | 58 |
| Ozempic | Semaglutide | 155 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 53 |
| Montelukast Sodium | Montelukast Sodium | 148 | 51 |
| Eliquis | Apixaban | 138 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 133 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 129 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 45 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 122 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 37 |
| Lisinopril | Lisinopril | 100 | 32 |
| Furosemide | Furosemide | 94 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 92 | 51 |
| Alendronate Sodium | Alendronate Sodium | 90 | 31 |
| Carvedilol | Carvedilol | 90 | 33 |
| Clobetasol Propionate | Clobetasol Propionate | 90 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 25 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 88 | suppressed |
| Mirtazapine | Mirtazapine | 87 | 35 |
| Promethazine Hcl | Promethazine Hcl | 84 | 54 |
| Methylprednisolone | Methylprednisolone | 83 | 66 |
| Naproxen | Naproxen | 81 | 59 |
| Azithromycin | Azithromycin | 80 | 66 |
| Meloxicam | Meloxicam | 79 | 46 |
| Glimepiride | Glimepiride | 76 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 75 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 28 |
| Valsartan | Valsartan | 71 | 19 |
| Telmisartan | Telmisartan | 70 | 23 |
| Farxiga | Dapagliflozin Propanediol | 68 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 29 |
| Enalapril Maleate | Enalapril Maleate | 65 | 21 |
| Clonazepam | Clonazepam | 64 | 21 |
| Ketoconazole | Ketoconazole | 64 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 20 |
| Januvia | Sitagliptin Phosphate | 56 | 16 |
| Donepezil Hcl | Donepezil Hcl | 53 | 22 |
| Folic Acid | Folic Acid | 53 | 26 |
| Allopurinol | Allopurinol | 52 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 51 | 51 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 45 |
| Xarelto | Rivaroxaban | 49 | 12 |
| Sertraline Hcl | Sertraline Hcl | 48 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 47 | 14 |
| Ramipril | Ramipril | 47 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Procto-Med Hc | Hydrocortisone | 46 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 45 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 14 |
| Linzess | Linaclotide | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 16 |
| Hydrocortisone | Hydrocortisone | 42 | 22 |
| Finasteride | Finasteride | 41 | 16 |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 12 |
| Azelastine Hcl | Azelastine Hcl | 39 | 20 |
| Clonidine Hcl | Clonidine Hcl | 38 | 13 |
| Nifedipine Er | Nifedipine | 38 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Sucralfate | Sucralfate | 35 | 17 |
| Ibuprofen | Ibuprofen | 34 | 28 |
| Potassium Chloride | Potassium Chloride | 34 | 13 |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 33 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 33 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 32 | 32 |
| Celecoxib | Celecoxib | 32 | 21 |
| Prednisone | Prednisone | 31 | 14 |
| Tramadol Hcl | Tramadol Hcl | 31 | 13 |
| Megestrol Acetate | Megestrol Acetate | 30 | 12 |
| Myrbetriq | Mirabegron | 30 | 11 |
| Pregabalin | Pregabalin | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | 12 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | 12 |
| Mupirocin | Mupirocin | 28 | 22 |
| Nitroglycerin | Nitroglycerin | 28 | 12 |
| Santyl | Collagenase Clostridium Hist. | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | 11 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Colchicine | Colchicine | 24 | 11 |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Atovaquone | Atovaquone | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Prolia | Denosumab | 21 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Dovato | Dolutegravir Sodium/Lamivudine | 20 | suppressed |
| Terconazole | Terconazole | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Diazepam | Diazepam | 18 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Gemtesa | Vibegron | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Famciclovir | Famciclovir | 15 | 15 |
| Metronidazole | Metronidazole | 15 | 13 |
| Nateglinide | Nateglinide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | 11 |
| Halobetasol Propionate | Halobetasol Propionate | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Darunavir | Darunavir | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Tivicay | Dolutegravir Sodium | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 12 | 12 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $955.24 · 55 records | Gilead Sciences, Inc. | AIRSUPRA, APRETUDE, AREXVY, Arikayce, Biktarvy, CABENUVA, DOVATO, EGRIFTA, FARXIGA, JARDIANCE, Ozempic, PAXLOVID, Rybelsus, TRELEGY ELLIPTA, TROGARZO, VOWST, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error